

PDX Data Sheet for COG-N-519x

Disease:	Neuroblastoma
Phase of Therapy:	Post-Chemotherapy (Progressive Disease), Post-mortem
Treatment:	ANBL00B1 (Chemotherapy, Surgery)
Disease Stage:	4
Gender:	Male
Age at diagnosis:	25 months
Race:	NA
Age at sample collection:	57.7 months
Source of culture:	Blood (autopsy) January 2014
Primary tumor site:	C74.9: Adrenal gland, NOS
Date Established:	March 2014
MYCN Patient:	NA
MYCN PDX:	Relative copy number – 243 copies
TH mRNA:	Expressed
p53 functionality:	NA
Telomere Mechanism:	TERT+++ , C-circle negative
ALK:	Wild Type
PDX RNAseq:	Available upon request
PDX WES:	Available upon request
Strain of Mice:	NSG or Athymic NuNu (recommended)
Injection Type:	Subcutaneous
Growth Properties:	10e6 cells minimum, 2 months to 1500mm ³ Please see Protocols section at https://www.cccells.org/protocols.php
Human vs. Mouse:	This PDX model has been tested and confirmed over multiple passages to be above 98% human cells.
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	The Childhood Cancer Repository has a matching direct-to-culture cell line available from this same patient – COG-N-519. The Childhood Cancer Repository has a matching hypoxic cell line grown at 5% O ₂ and 2% O ₂ available from this same patient – COG-N-519h and COG-N-519h2.
h-IMPACT Profile I IDEXX:	PCR evaluation of EBV, HAAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV2, LCMV, Mycoplasma sp., Seoul, Sin Nombre, VZV were all negative.



PDX Data Sheet for COG-N-519x

Cell Line Name: COG-N-519x

References:

1. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. *Sci Data*. 2017;4:170033. PMID: 28350380
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369315/>



PDX Data Sheet for COG-N-519x

PDX Name: COG-N-519x

H&E slides